Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy

Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limi...

Full description

Saved in:
Bibliographic Details
Main Authors: Pottier, Charles Albert (Author) , Fresnais, Margaux (Author) , Longuespée, Rémi (Author)
Format: Article (Journal)
Language:English
Published: 20 March 2020
In: Cancers
Year: 2020, Volume: 12, Issue: 3
ISSN:2072-6694
DOI:10.3390/cancers12030731
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers12030731
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/12/3/731
Get full text
Author Notes:Charles Pottier, Margaux Fresnais, Marie Gilon, Guy Jérusalem, Rémi Longuespée and Nor Eddine Sounni
Description
Summary:Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limited by the appearance of resistance or adverse effects. In this review, we summarize the main features of RTKs and their inhibitors (RTKIs), their current use in oncology, and mechanisms of resistance. We also describe the technological advances of artificial intelligence, chemoproteomics, and microfluidics in elaborating powerful strategies that could be used in providing more efficient and selective small molecules inhibitors of RTKs. Finally, we discuss the interest of therapeutic combination of different RTKIs or with other molecules for personalized treatments, and the challenge for effective combination with less toxic and off-target effects.
Item Description:Gesehen am 05.08.2020
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers12030731